Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy’
Crossref DOI link: https://doi.org/10.1038/bjc.2017.58
Published Online: 2017-03-21
Published Print: 2017-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Imafuku, Keisuke
Yoshino, Koji
Yamaguchi, Kei
Tsuboi, Satoshi
Ohara, Kuniaki
Hata, Hiroo
Text and Data Mining valid from 2017-03-21
Article History
First Online: 21 March 2017
Competing interests
: The authors declare no conflict of interest.